Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes f...

Full description

Bibliographic Details
Main Authors: Emily M. J. Fennell, Lucas J. Aponte-Collazo, Wimal Pathmasiri, Blake R. Rushing, Natalie K. Barker, Megan C. Partridge, Yuan-Yuan Li, Cody A. White, Yoshimi E. Greer, Laura E. Herring, Stanley Lipkowitz, Susan C. J. Sumner, Edwin J. Iwanowicz, Lee M. Graves
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Pharmacology
Subjects:
ClpP activators
CLPP
mitochondria
multi-omics
breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1136317/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1136317/full

Similar Items